Overview

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.

Phase:

PHASE3

Details

Lead Sponsor:

Neurocrine Biosciences

Treatments:

valbenazine